Banking on the future: biobanking for "omics" approaches to biomarker discovery for Opisthorchis-induced cholangiocarcinoma in Thailand.

Cholangiocarcinoma (CCA)--bile duct cancer--is associated with late presentation, poses challenges for diagnosis, and has high mortality. These features t highlight the desperate need for biomarkers than can be measured early and in accessible body fluids such as plasma of people at risk for developing this lethal cancer. In this manuscript, we address previous limitations in the discovery stage of biomarker(s) for CCA and indicate how new generation of "omics" technologies could be used for biomarker discovery in Thailand. A key factor in the success of this biomarker program for CCA is the combination of cutting edge technology with strategic sample acquisition by a biorepositories.

[1]  B. Sripa Pathobiology of opisthorchiasis: an update. , 2003, Acta tropica.

[2]  M. Haswell-Elkins,et al.  Epidemiology of Opisthorchis viverrini. , 2003, Acta tropica.

[3]  G. Gores,et al.  Cholangiocarcinoma: modern advances in understanding a deadly old disease. , 2006, Journal of hepatology.

[4]  Y. Mizuguchi,et al.  MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. , 2009, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[5]  D. Larsimont,et al.  The role of the pathologist in tissue banking: European Consensus Expert Group Report , 2010, Virchows Archiv.

[6]  S. Taylor-Robinson,et al.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[7]  M. Haswell-Elkins,et al.  Relationship between intensity of Opisthorchis viverrini infection and hepatobiliary disease detected by ultrasonography , 1992, Journal of gastroenterology and hepatology.

[8]  S. Lowe,et al.  miR-221 overexpression contributes to liver tumorigenesis , 2009, Proceedings of the National Academy of Sciences.

[9]  Lingyun Huang,et al.  Serum levels of variants of transthyretin down‐regulation in cholangiocarcinoma , 2008, Journal of cellular biochemistry.

[10]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[11]  C. Pairojkul,et al.  Cholangiocarcinoma: lessons from Thailand , 2008, Current opinion in gastroenterology.

[12]  D. Brenner,et al.  What goes up must come down: The emerging role of microRNA in fibrosis , 2011, Hepatology.

[13]  G. Gores,et al.  Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment , 2008, Hepatology.

[14]  M. Haswell-Elkins,et al.  Reversal of biliary tract abnormalities associated with Opisthorchis viverrini infection following praziquantel treatment. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  J. Utzinger,et al.  Emerging Foodborne Trematodiasis , 2005, Emerging infectious diseases.

[16]  P. Selby,et al.  Circulating markers of biliary malignancy: opportunities in proteomics? , 2008, The Lancet. Oncology.

[17]  R. Andrews,et al.  Opisthorchis viverrini: an underestimated parasite in world health. , 2008, Trends in parasitology.

[18]  M. Haswell-Elkins,et al.  Cross‐sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high‐risk area in northeast thailand , 1994, International journal of cancer.

[19]  D. Parkin,et al.  Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  Yoshiki Murakami,et al.  The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families , 2011, PloS one.

[21]  S. Pinlaor,et al.  Hepatobiliary changes, antibody response, and alteration of liver enzymes in hamsters re-infected with Opisthorchis viverrini. , 2004, Experimental parasitology.

[22]  Banchob Sripa,et al.  Liver Fluke Induces Cholangiocarcinoma , 2007, PLoS medicine.

[23]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[24]  B. Sitek,et al.  Cell-based proteome analysis: the first stage in the pipeline for biomarker discovery. , 2009, Biochimica et biophysica acta.

[25]  Eiliv Lund,et al.  Systems Epidemiology in Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[26]  H. Esumi,et al.  Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation in human carcinogenesis. , 1994, Mutation research.

[27]  Alex Loukas,et al.  Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin‐6 , 2009, Hepatology.

[28]  P. Pisani,et al.  Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand , 2004, Tropical medicine & international health : TM & IH.

[29]  B. Kramer,et al.  Trends in biomarker research for cancer detection. , 2001, The Lancet. Oncology.

[30]  G. Gores,et al.  MicroRNA‐21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3 , 2009, Hepatology.

[31]  P. Sithithaworn,et al.  Opisthorchis viverrini and opisthorchiasis: the 21st century review. , 2003, Acta tropica.